BioCentury
ARTICLE | Clinical News

ReGenerCell: Phase IV data

April 4, 2016 7:00 AM UTC

An open-label, European Phase IV trial in 52 patients with chronic venous leg ulcers showed that ReGenerCell plus standard of care (SOC) non-significantly improved the rate of complete wound closure v...